The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1459
January 5, 2015
View Complete Issue         Table of Contents 2019 
Trumenba: A Serogroup B Meningococcal Vaccine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Trumenba: A Serogroup B Meningococcal Vaccine
January 5, 2015 (Issue: 1459)
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Trumenba: A Serogroup B Meningococcal Vaccine
Article code: 1459d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.